Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage (COGHIC-AV45)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by University Hospital, Toulouse
Sponsor:
Collaborators:
Avid Radiopharmaceuticals
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by (Responsible Party):
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT01619709
First received: June 12, 2012
Last updated: November 3, 2014
Last verified: November 2014
  Purpose

To evaluate Pet AV-45 Amyloid imaging in the etiological diagnosis of primary non traumatic intracerebral hemorrhage (Cerebral Amyloid Angiopathy and hypertension related hemorrhage).We hypothesize that patients with lobar hemorrhage (probably related to Cerebral Amyloid Angiopathy) will have a greater AV45 cortical binding than patients with deep hemorrhage (probably related to hypertension).


Condition Intervention
Intracerebral Hemorrhage
Other: Pet AV-45

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage

Resource links provided by NLM:


Further study details as provided by University Hospital, Toulouse:

Primary Outcome Measures:
  • Pet-AV45 cortical binding [ Time Frame: Acute phase of intracerebral hemorrhage ie during the first month after hemorrhage onset. ] [ Designated as safety issue: No ]
    Method of administration: a bolus IV injection (less than 1 minute of injection time) of 5 MBq / kg with a maximum of 370MBq. The activity corresponding to a 70 kg individual is 350 MBq and corresponds to an effective dose of 12.25mSv (0.035mSv/MBq)


Secondary Outcome Measures:
  • cerebral microbleeds number and distribution on T2EG MRI sequence [ Time Frame: Acute phase of intracerebral hemorrhage ie during the first month ] [ Designated as safety issue: No ]
    Review safe after checking against usual contraindications (pacemaker, ocular foreign body), painless, lasting about 45 minutes, during which a detailed analysis of the brain will be performed

  • White Matter Lesions Volume on 3D-FLAIR MRI sequence [ Time Frame: Acute phase of intracerebral hemorrhage ie during the first month ] [ Designated as safety issue: No ]
    Review safe after checking against usual contraindications (pacemaker, ocular foreign body), painless, lasting about 45 minutes, during which a detailed analysis of the brain will be performed

  • Cortical thickness and hippocampal volume on 3D-T1 MRI sequence [ Time Frame: Acute phase of intracerebral hemorrhage ie during the first month ] [ Designated as safety issue: No ]
    Review safe after checking against usual contraindications (pacemaker, ocular foreign body), painless, lasting about 45 minutes, during which a detailed analysis of the brain will be performed

  • Neuropsychological performances [ Time Frame: three months after hemorrhage onset. ] [ Designated as safety issue: No ]
    a neuropsychological examination (tests of memory, language and attention) will be realized. This examination will last approximately 60 minutes and take place in consultation with neurology


Estimated Enrollment: 70
Study Start Date: January 2012
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
lobar hemorrhage group
PET AV-45 in patients with cortical or corticosubcortical hemorrhage (involving predominantly the cortex and underlying white matter)
Other: Pet AV-45
AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
Other Name: PET AV-45 (Florbetapir F 18) Cerebral Amyloid imaging
deep hemorrhage group
PET AV-45patients with subcortical hemorrhage (involving predominately the basal ganglia, periventricular white matter, or internal capsule).
Other: Pet AV-45
AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
Other Name: PET AV-45 (Florbetapir F 18) Cerebral Amyloid imaging

Detailed Description:

Cerebral Amyloid Angiopathy (CAA) and hypertension related hemorrhage are the main causes of non traumatic primary intracerebral hemorrhage. In vivo diagnosis of these two cerebral diseases may be difficult and is based on hematoma location and pattern of cerebral microbleeds (CMB) distribution. We aimed to evaluate a multimodal approach including brain MRI, Pet AV-45 Amyloid imaging and neuropsychological assessment to improve etiological diagnosis of primary intracerebral hemorrhage. 70 patients with acute primary non traumatic intracerebral hemorrhage will be prospectively included and two groups will be compared: lobar hemorrhage group and deep hemorrhage group. Brain MRI, Pet AV-45 Cerebral Amyloid imaging (during the first month) and neuropsychological assessment (Three months later) are performed. Differences between the two groups are evaluated for AV45 cortical binding, CMB distribution, White Matter Lesions and cognitive profile.

  Eligibility

Ages Eligible for Study:   40 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age : 40-90 years,
  • Non traumatic primary intracerebral hemorrhage during acute phase (less than 30 days from hemorrhage onset) confirmed on brain imaging (CT and/or MRI).
  • Correct visual, hearing and language functions to perform neuropsychological tests.
  • Written consent of patient

Exclusion Criteria:

  • Secondary causes of intracerebral hemorrhage : vascular malformations (Arteriovenous malformation, intracranial aneurysm, Cavernous angioma, dural arteriovenous fistula), cerebral venous thrombosis, intracranial neoplasm, coagulopathy, vascularitis, Cocaine or alcohol use, Hemorrhagic ischemic stroke.
  • Pregnancy
  • Contraindication to MRI
  • progressive neoplasm
  • Cognitive impairment secondary to progressive neurological disease
  • Depression,
  • Drug addiction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01619709

Contacts
Contact: Nicolas Raposo, MD (0)5 61 77 76 40 ext 33 raposo.n@chu-toulouse.fr
Contact: Jérémie Parienté, MD (0)5 61 77 76 40 ext 33 pariente.j@chu-toulouse.fr

Locations
France
Service de neurologie Recruiting
Toulouse, France, 31059
Contact: Nicolas Raposo, MD    (0)5 61 77 76 40 ext 33    raposo.n@chu-toulouse.fr   
Sponsors and Collaborators
University Hospital, Toulouse
Avid Radiopharmaceuticals
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Principal Investigator: Nicolas Raposo, MD University Hospital, Toulouse
  More Information

No publications provided

Responsible Party: University Hospital, Toulouse
ClinicalTrials.gov Identifier: NCT01619709     History of Changes
Other Study ID Numbers: 1122302, AOL 2011
Study First Received: June 12, 2012
Last Updated: November 3, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by University Hospital, Toulouse:
Intracerebral Hemorrhage
Cerebral Amyloid angiopathy
Amyloid imaging
18F-AV-45

Additional relevant MeSH terms:
Cerebral Hemorrhage
Cognition Disorders
Hemorrhage
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Intracranial Hemorrhages
Mental Disorders
Nervous System Diseases
Pathologic Processes
Vascular Diseases

ClinicalTrials.gov processed this record on November 25, 2014